Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Cardiology Journal
MENU
Shortcuts Submit an article CJ Guide for Authors (new) Recent articles Special collections Ahead Of Print APIS-S Online Calculator OCT Contrast Calculator Reviewers 2022

open access

Vol 29, No 1 (2022)
Experts' Viewpoint
Submitted: 2021-10-26
Accepted: 2021-10-26
Published online: 2021-11-17
View PDF Download PDF file View HTML
Get Citation

Management of dyslipidemia in Poland: Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. The Fourth Declaration of Sopot

Filip M. Szymański1, Agnieszka Mickiewicz2, Grzegorz Dzida3, Iwona Gorczyca-Głowacka4, Dariusz Kozłowski5, Krystyna Widecka6, Zbigniew Krasiński7, Adam Kobayashi89, Dagmara Hering10, Katarzyna Mizia-Stec11, Jarosław D. Kasprzak12, Tomasz Zubilewicz13, Krzysztof Narkiewicz10, Marek Koziński14, Anna E. Płatek15, Anna Ryś-Czaporowska16, Beata Chełstowska17, Stefan Grajek18, Marcin Wełnicki19, Artur Mamcarz19, Marcin Barylski20, Beata Wożakowska-Kapłon4, Miłosz J. Jaguszewski2, Marcin Gruchała2, Krzysztof J. Filipiak21
DOI: 10.5603/CJ.a2021.0147
·
Pubmed: 34811718
·
Cardiol J 2022;29(1):1-26.
Affiliations
  1. Department of Civilization Diseases, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, Poland
  2. 1st Department of Cardiology, Medical University of Gdansk, Poland
  3. Chair and Department of Internal Diseases, Medical University of Lublin, Poland
  4. 1st Department of Cardiology and Electrotherapy, Swietokrzyskie Cardiology Center, Faculty of Medical and Health Sciences, The University of Jan Kochanowski, Kielce, Poland
  5. Department of Cardiology and Electrotherapy, Medical University of Gdansk, Poland
  6. Department of Hypertension and Internal Medicine, Pomeranian Medical University, Szczecin, Poland
  7. Department of Vascular and Endovascular Surgery, Angiology and Phlebology, Institute of Surgery, Poznan University of Medical Sciences, Poznan, Poland
  8. Department of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, Poland
  9. Department of Neurology with Stoke Unit, St. John Paul II Mazovian Provincial Hospital in Siedlce, Poland
  10. Department of Hypertension and Diabetology, Medical University of Gdansk, Poland
  11. 1st Department of Cardiology, Medical University of Silesia, Katowice, Poland
  12. 1st Department of Cardiology, Medical University of Lodz, Poland
  13. Department of Vascular Surgery and Angiology, Medical University of Lublin, Poland
  14. Department of Cardiology and Internal Diseases, Institute of Maritime and Tropical Medicine, Gdynia, Poland
  15. Department of Biophysics, Physiology and Pathophysiology, Medical University of Warsaw, Poland
  16. 1st Department of Cardiology, Medical University of Warsaw, Poland
  17. Department of Biochemistry and Laboratory Diagnostics, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, Poland
  18. 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
  19. 3rd Department of Cardiology and Internal Diseases, Medical University of Warsaw, Poland
  20. Department of Internal Medicine and Cardiac Rehabilitation, Medical University of Lodz, Poland
  21. Institute of Clinical Sciences, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland

open access

Vol 29, No 1 (2022)
POSITION PAPER
Submitted: 2021-10-26
Accepted: 2021-10-26
Published online: 2021-11-17

Abstract

Not available

Abstract

Not available

Full Text:

View PDF Download PDF file View HTML
Get Citation
About this article
Title

Management of dyslipidemia in Poland: Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. The Fourth Declaration of Sopot

Journal

Cardiology Journal

Issue

Vol 29, No 1 (2022)

Article type

Experts' Viewpoint

Pages

1-26

Published online

2021-11-17

Page views

7178

Article views/downloads

3102

DOI

10.5603/CJ.a2021.0147

Pubmed

34811718

Bibliographic record

Cardiol J 2022;29(1):1-26.

Authors

Filip M. Szymański
Agnieszka Mickiewicz
Grzegorz Dzida
Iwona Gorczyca-Głowacka
Dariusz Kozłowski
Krystyna Widecka
Zbigniew Krasiński
Adam Kobayashi
Dagmara Hering
Katarzyna Mizia-Stec
Jarosław D. Kasprzak
Tomasz Zubilewicz
Krzysztof Narkiewicz
Marek Koziński
Anna E. Płatek
Anna Ryś-Czaporowska
Beata Chełstowska
Stefan Grajek
Marcin Wełnicki
Artur Mamcarz
Marcin Barylski
Beata Wożakowska-Kapłon
Miłosz J. Jaguszewski
Marcin Gruchała
Krzysztof J. Filipiak

References (58)
  1. Wożakowska-Kapłon B, Filipiak KJ, Mamcarz A, et al. [Actual problems of dyslipidaemia treatment in Poland - 2nd Declaration of Sopot. Experts' Group Consensus endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy]. Kardiol Pol. 2014; 72(9): 847–853.
    CrossRefPubMed
  2. Filipiak KJ, Cybulska B, Dudek D, et al. Aktualne problemy terapii dyslipidemii w Polsce — Deklaracja Sopocka. Stanowisko ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Choroby Serca i Naczyń. 2011; 8: 1–4.
  3. Szymański FM, Barylski M, Cybulska B, et al. Recommendation for the management of dyslipidemia in Poland - Third Declaration of Sopot. Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. Cardiol J. 2018; 25(6): 655–665.
    CrossRefPubMed
  4. Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111–188.
    CrossRefPubMed
  5. Akioyamen LE, Genest J, Shan SD, et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open. 2017; 7(9): e016461.
    CrossRefPubMed
  6. McGowan MP, Hosseini Dehkordi SH, Moriarty PM, et al. Diagnosis and treatment of heterozygous familial hypercholesterolemia. J Am Heart Assoc. 2019; 8(24): e013225.
    CrossRefPubMed
  7. Bruckert É, Gallo A. L’hypercholestérolémie familiale. Bull Acad Natle Méd. 2017; 201(7-9): 1323–1334.
    CrossRef
  8. Mickiewicz A, Chmara M, Futema M, et al. Efficacy of clinical diagnostic criteria for familial hypercholesterolemia genetic testing in Poland. Atherosclerosis. 2016; 249: 52–58.
    CrossRefPubMed
  9. Rynkiewicz A, Cybulska B, Banach M, et al. Polish Lipid Expert Forum. [Management of familial heterozygous hypercholesterolaemia. Position paper of the Polish Lipid Expert Forum]. Kardiol Pol. 2013; 71(1): 107–111.
    PubMed
  10. Sturm AC, Knowles JW, Gidding SS, et al. Cascade screening for familial hypercholesterolemia and the use of genetic testing. JAMA. 2017; 318(4): 381–382.
    CrossRefPubMed
  11. Sharifi M, Futema M, Nair D, et al. Polygenic hypercholesterolemia and cardiovascular disease risk. Curr Cardiol Rep. 2019; 21(6): 43.
    CrossRefPubMed
  12. Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet. 2013; 381(9874): 1293–1301.
    CrossRefPubMed
  13. Futema M, Bourbon M, Williams M, et al. Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia. Atherosclerosis. 2018; 277: 457–463.
    CrossRefPubMed
  14. Pająk A, Szafraniec K, Polak M, et al. WOBASZ Investigators. Changes in the prevalence, treatment, and control of hypercholesterolemia and other dyslipidemias over 10 years in Poland: the WOBASZ study. Pol Arch Med Wewn. 2016; 126(9): 642–652.
    CrossRefPubMed
  15. Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE Investigators. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016; 23(6): 636–648.
    CrossRefPubMed
  16. Reiner Ž, De Backer G, Fras Z, et al. EUROASPIRE Investigators. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey. Atherosclerosis. 2016; 246: 243–250.
    CrossRefPubMed
  17. Bandosz P, O'Flaherty M, Drygas W, et al. Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study. BMJ. 2012; 344: d8136.
    CrossRefPubMed
  18. Catapano AL, Graham I, De Backer G, et al. ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016; 37(39): 2999–3058.
    CrossRefPubMed
  19. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol. 2011; 9(3): 258–270.
    CrossRefPubMed
  20. Stroes ES, Thompson PD, Corsini A, et al. European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015; 36(17): 1012–1022.
    CrossRefPubMed
  21. Piepoli MF, Hoes AW, Agewall S, et al. Authors/Task Force Members, Additional Contributor: Simone Binno (Italy), Document Reviewers:. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol. 2016; 23(11): NP1–NP96.
    CrossRefPubMed
  22. Visseren FLJ, Mach F, Smulders YM, et al. ESC National Cardiac Societies, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–3337.
    CrossRefPubMed
  23. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm – 2017 Executive Summary. Endocr Pract. 2017; 23(2): 207–238.
    CrossRefPubMed
  24. Robinson JG, Rosenson RS, Farnier M, et al. Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials. J Am Coll Cardiol. 2017; 69(5): 471–482.
    CrossRefPubMed
  25. Brunner F, Waldeyer C, Ojeda F, et al. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. The Lancet. 2019; 394(10215): 2173–2183.
    CrossRef
  26. Schoeneck M, Iggman D. The effects of foods on LDL cholesterol levels: A systematic review of the accumulated evidence from systematic reviews and meta-analyses of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2021; 31(5): 1325–1338.
    CrossRefPubMed
  27. Stefanick ML, Mackey S, Sheehan M, et al. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med. 1998; 339(1): 12–20.
    CrossRefPubMed
  28. Varady KA, Jones PJH. Combination diet and exercise interventions for the treatment of dyslipidemia: an effective preliminary strategy to lower cholesterol levels? J Nutr. 2005; 135(8): 1829–1835.
    CrossRefPubMed
  29. Szymanski FM, Semczuk-Kaczmarek K, Kuna P. "Health outcomes in COPD smokers using heated tobacco products: a 3‑year follow‑up: comment". Intern Emerg Med. 2021; 16(8): 2331–2333.
    CrossRefPubMed
  30. deZeeuw D. Different renal protective effects of atorvastatin and rosuvastatin in diabetic and non-diabetic renal patients with proteinuria. Results of the PLANET trials. 2010 European Dialysis and Transplant Association Congress. Munich, Germany, June 27, 2010.
  31. Abe M, Maruyama N, Okada K, et al. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb. 2011; 18(11): 1018–1028.
    CrossRefPubMed
  32. Nissen SE, Nicholls SJ, Sipahi I, et al. ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006; 295(13): 1556–1565.
    CrossRefPubMed
  33. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011; 365(22): 2078–2087.
    CrossRefPubMed
  34. Mickiewicz A, Futema M, Ćwiklinska A, et al. Higher responsiveness to rosuvastatin in polygenic versus monogenic hypercholesterolaemia: a propensity score analysis. Life (Basel). 2020; 10(5).
    CrossRefPubMed
  35. Wójcik C. Emerging lipid lowering agents targeting LDL cholesterol. Postgrad Med. 2020 [Epub ahead of print].
    CrossRefPubMed
  36. Surma S, Romańczyk M, Filipiak KJ. Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia. Cardiol J. 2021 [Epub ahead of print].
    CrossRefPubMed
  37. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009; 301(22): 2331–2339.
    CrossRefPubMed
  38. Wei WQ, Li X, Feng Q, et al. LPA variants are associated with residual cardiovascular risk in patients receiving statins. Circulation. 2018; 138(17): 1839–1849.
    CrossRefPubMed
  39. Nicholls SJ, Bubb KJ. The riskier lipid: what is on the HORIZON for lipoprotein (a) and should there be lp(a) screening for all? Curr Cardiol Rep. 2021; 23(8): 97.
    CrossRefPubMed
  40. Cegla J, Neely RD, France M, et al. HEART UK Medical, Scientific and Research Committee. HEART UK consensus statement on Lipoprotein(a): A call to action. Atherosclerosis. 2019; 291: 62–70.
    CrossRefPubMed
  41. Rhainds D, Brodeur MR, Tardif JC. Lipoprotein (a): when to measure and how to treat? Curr Atheroscler Rep. 2021; 23(9): 51.
    CrossRefPubMed
  42. Leebmann J, Roeseler E, Julius U, et al. Pro(a)LiFe Study Group*. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation. 2013; 128(24): 2567–2576.
    CrossRefPubMed
  43. Moriarty PM, Gray JV, Gorby LK. Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease. J Clin Lipidol. 2019; 13(6): 894–900.
    CrossRefPubMed
  44. Mickiewicz A, Marlega J, Kuchta A, et al. Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland. J Clin Apher. 2021; 36(3): 370–378.
    CrossRefPubMed
  45. Szarek M, Bittner VA, Aylward P, et al. ODYSSEY OUTCOMES Investigators. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020; 41(44): 4245–4255.
    CrossRefPubMed
  46. Banach M, Mikhailidis DP. Statin intolerance: some practical hints. Cardiol Clin. 2018; 36(2): 225–231.
    CrossRefPubMed
  47. Alonso R, Cuevas A, Cafferata A. Diagnosis and management of statin intolerance. J Atheroscler Thromb. 2019; 26(3): 207–215.
    CrossRefPubMed
  48. Ward NC, Watts GF, Eckel RH. Statin toxicity. Circ Res. 2019; 124(2): 328–350.
    CrossRefPubMed
  49. Diaconu CC, Iorga RA, Furtunescu F, et al. Statin intolerance: new data and further options for treatment. Curr Opin Cardiol. 2021; 36(4): 487–493.
    CrossRefPubMed
  50. Bohula EA, Giugliano RP, Cannon CP, et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015; 132(13): 1224–1233.
    CrossRefPubMed
  51. Navarese EP, Kolodziejczak M, Kereiakes DJ, et al. Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies for acute coronary syndrome: a narrative review. Ann Intern Med. 2016; 164(9): 600–607.
    CrossRefPubMed
  52. Robinson JG, Farnier M, Krempf M, et al. ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16): 1489–1499.
    CrossRefPubMed
  53. Sabatine MS, Giugliano RP, Wiviott SD, et al. Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16): 1500–1509.
    CrossRefPubMed
  54. Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol. 2014; 54: 273–293.
    CrossRefPubMed
  55. Szymański F, Filipiak K, Wożakowska-Kapłon B, et al. Dyslipidemia aterogenna w codziennej praktyce — interdyscyplinarny konsensus polskich ekspertów. Folia Cardiol. 2017; 12(1): 33–49.
    CrossRef
  56. Zhu L, Hayen A, Bell KJL. Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study. Cardiovasc Diabetol. 2020; 19(1): 28.
    CrossRefPubMed
  57. Sliż D, Filipiak KJ, Naruszewicz M, et al. Standards of statin usage in Poland in high-risk patients: 3ST-POL study results. Kardiol Pol. 2013; 71(3): 253–259.
    CrossRefPubMed
  58. Averna M, Banach M, Bruckert E, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 2021; 325: 99–109.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl